- Home
- GCV vs BYSI Comparison
GCV vs BYSI Comparison
Compare GCV & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCV | BYSI |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.1M | 79.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GCV | BYSI |
|---|---|---|
| Price | $4.34 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 57.9K | ★ 67.5K |
| Earning Date | 01-01-0001 | 02-11-2026 |
| Dividend Yield | ★ 13.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $0.98 |
| 52 Week High | $4.58 | $3.44 |
Technical Indicators
Market Signals| Indicator | GCV | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 45.14 |
| Support Level | $4.32 | $1.62 |
| Resistance Level | $4.39 | $1.77 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 89.69 | 73.08 |
Price Performance
Historical ComparisonAbout GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.